Study populations The study population with obesity The analyses for the association of semaglutide with both incident and recurrent diagnosis of AUD in patients with obesity were restricted to a starting date of 6/2021 when semaglutide was approved in the US for weight management as Wegovy and an ending date of 12/2022, which allowed for a 12-month follow-up period by the time of data collection and analysis on January 26, 2024
investor.lilly.com 13NIH / NIDDK (2024)
Its research profile makes it especially relevant for studies focused on metabolic flexibility, mitochondrial energy output, exercise-related signaling, cardiometabolic models, fatty acid utilization, and cellular energy demand
G., Hayes, J
Rose Hydrosol - Rosa damascena Resilient Rose Hydrosol prepares the pores to receive the hydration it adores
Emerging agents like tirzepatide and orforglipron demonstrate the expanding horizon of GLP-1-based therapies, offering enhanced efficacy and novel mechanisms of action
